Organisation paid for research Program year 2024 Source: CMS Open Payments

Clear Vision Research

Neither a doctor nor a teaching hospital

Research payments

$17,022

10 payments

Through program year 2024, Clear Vision Research is reported as receiving $17,022 in research payments, across 10 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $3,000 3
2022 Research $7,497 1
2021 Research $804 1
2020 Research $1,434 2
2019 Research $4,287 3

Breakdown

Who paid Research payments · program years 2019–2024
  1. Celgene Corporation $10,497 4 payments
  2. Allergan Inc. $6,346 4 payments
  3. Bausch Health US, LLC $179 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) $7,497 1 payment
  2. A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Medi2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed Or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha Therapy $4,108 1 payment
  3. Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease $1,000 1 payment
  4. A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease $1,000 1 payment
  5. An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease $1,000 1 payment
  6. A Phase 2, Randomized, Double-Blind Placebo-Controlled Parallel-Group, Dose Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Aged 12-17) With Irritable Bowel Syndrome With Diarrhea (Ibs-D) $804 1 payment
  7. A?Pediatric (12-17) Clinical Pharmacology/Efficacy/Safety Study $804 1 payment
  8. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $630 1 payment
  9. A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed By Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohns Disease $179 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record